

**Designing pH-Triggered Drug Release Iron Oxide Nanocomposites for MRI
Guided Photothermal-Chemoembolization Therapy of Liver Orthotopic Cancer**

Fengyong Liu,^{*a} Xin Li,^a Yangyang Li,^{*bc} Yuchen Qi,^c Hongjun Yuan,^a Jian He,^c Wanlin
Li,^c and Min Zhou^{*bcd}

^a Department of Interventional Radiology, The First Medical Center of Chinese PLA
General Hospital, Beijing 100853, China.

^b Department of Nuclear Medicine & Key Laboratory of Cancer Prevention and
Intervention, National Ministry of Education, The Second Affiliated Hospital, School of
Medicine, Zhejiang University, Hangzhou 310009, China

^c Institute of Translational Medicine, Zhejiang University, Hangzhou 310009, China

^d State Key Laboratory of Modern Optical Instrumentations, Zhejiang University,
Hangzhou 310058, China

E-mail addresses: zhoum@zju.edu.cn (Min Zhou); fengyongliu@aliyun.com
(Fengyong Liu); 11526010@zju.edu.cn (Yangyang Li)




Figure S1 (a) DLS size distribution of hematite nanoparticles after PDA modification and DOX loading process. (b) Zeta potentials of Fe₂O₃, Fe₂O₃@PDA, DOX molecules and Fe₂O₃-PDA-DOX, respectively.




Figure S2 Relative cell viability of N1S1 hepatoma cell incubated with PDA coated Fe₂O₃ nanoparticles with varied concentrations for 24 h.

■ Control ■ Lipidol+DOX ■ Lipidol+Fe₂O₃-PDA-DOX ■ Lipidol+Fe₂O₃-PDA-DOX+NIR




Figure S3 Liver and kidney toxicity (ALT, AST, CREA, and TBIL) assessment during the therapeutic process

